Picture of Amarantus Bioscience Holdings logo

AMBS Amarantus Bioscience Holdings Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-67.55%
3m-91.57%
6m-90.54%
1yr-93.29%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-93.75%
50d MA-87.71%
200d MA-87.93%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 201931st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2019 / 2020

Blurred out image of Amarantus Bioscience Holdings EPS forecast chart

Profile Summary

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Directors

Last Annual
December 31st, 2018
Last Interim
March 31st, 2016
Incorporated
March 22nd, 2013
Public Since
September 29th, 2008
No. of Employees
10
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
630,607,411

AMBS Share Price Performance

Upcoming Events for AMBS

Similar to AMBS

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ